Indaxol 30/100/300 30 mg/ 100 mg/ 300 mg Concentrate for solution for infusion
PDF Leaflet Revision Date: 3 August 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Palliative treatment of advanced cancers including ovarian, breast, and lung.
Dosage (summary)
175 mg/m2 IV over 3 hours every 3 weeks; adjust for hepatic impairment.
Special Populations
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; may cause fetal harm.
Key Drug Interactions
- CYP2C8 and CYP3A4 inhibitors
- Cisplatin
- Doxorubicin
Contraindications
- Severe hypersensitivity to paclitaxel
- Neutrophils < 1500/mm3
- Lactation
Common side effects
- Neutropenia
- Peripheral neuropathy
- Hypersensitivity reactions
Counselling Points
- Premedicate to reduce hypersensitivity risk
- Monitor blood counts regularly
- Avoid pregnancy during treatment
Serious warnings
- Severe hypersensitivity reactions
- Bone marrow suppression
- Cardiac conduction abnormalities
Important Disclaimer
The Indaxol 30/100/300 30 mg/ 100 mg/ 300 mg Concentrate for solution for infusion professional information leaflet below is the property of Ruby Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
